Click the button above to connect with us and make an appointment to speak with a RINVOQ product specialist.
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.1
*The statement ‘First and only once-daily, oral advanced treatment for Crohn's disease’ is valid as of November 2022.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
REFERENCE
- RINVOQ Summary of Product Characteristics.
[Affiliates to insert local adverse events reporting websites]
ALL-RNQG-220167 Date of preparation: November 2022
Adverse events should also be reported to AbbVie on GBPV@abbvie.com